191 related articles for article (PubMed ID: 27734521)
1. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
2. Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab.
Padate BP; Keidan J
Clin Lab Haematol; 2006 Feb; 28(1):69-71. PubMed ID: 16430465
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
4. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
5. Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab.
de Souza KJ; Ferro RS; Prestes-Carneiro LE; Carrilho PAM; Vasconcelos DM
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):13-17. PubMed ID: 29094629
[TBL] [Abstract][Full Text] [Related]
6. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
7. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
8. Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
Chan H; Jackson S; McLay J; Knox A; Lee J; Wang S; Issa S
Leuk Lymphoma; 2016 Nov; 57(11):2584-92. PubMed ID: 26943235
[TBL] [Abstract][Full Text] [Related]
9. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
[No Abstract] [Full Text] [Related]
10. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
12. Fatal interstitial pneumonitis related to rituximab-containing regimen.
Herishanu Y; Polliack A; Leider-Trejo L; Grieff Y; Metser U; Naparstek E
Clin Lymphoma Myeloma; 2006 Mar; 6(5):407-9. PubMed ID: 16640819
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
[No Abstract] [Full Text] [Related]
14. Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
Delage L; Manzoni D; Quinquenet C; Fontaine J; Maarek A; Chabane K; Mosnier I; Hayette S; Callet-Bauchu E; Grange B; Plesa A; Sujobert P
Haematologica; 2019 Mar; 104(3):e114-e116. PubMed ID: 30545922
[No Abstract] [Full Text] [Related]
15. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
[TBL] [Abstract][Full Text] [Related]
16. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
17. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
19. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
20. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
Salmasi G; Li M; Sivabalasundaram V; Panzarella T; Tsang R; Kukreti V; Crump M; Kuruvilla J
Leuk Lymphoma; 2015 Jun; 56(6):1659-64. PubMed ID: 25356925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
